Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference

Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference

2024.09.17
From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for international academic exchange and cooperation. During the event, Hematology Frontier invited Dr. Wei Sang from The Affiliated Hospital of Xuzhou Medical University to provide an in-depth analysis of CAR-T cell therapy in different hematologic malignancies and explore strategies for optimizing treatment outcomes.
EBMT China’s Voice | Professors Xiaoyan Ke and Kai Hu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients

EBMT China’s Voice | Professors Xiaoyan Ke and Kai Hu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients

2024.09.15
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Xiaoyan Ke from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Kai Hu from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.
Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

2024.09.13
On July 2, 2024, the "ADC High-Level Closed-Door Seminar," chaired by Vice President Yong Yang of China Pharmaceutical University and President Jin Li of Shanghai Gaobo Oncology Hospital, was grandly held in Shanghai. The seminar explored the current status and future of ADC development. During the event, Oncology Frontier interviewed Professor Baohui Han from the Shanghai Chest Hospital . Combining recent ASCO conference updates, Professor Han analyzed the efficacy results and safety management points of ADC treatment in NSCLC and shared insights on the future prospects of ADC development.
Annual Review | Academician Xu Zhang: Chinese Doctors Leading a New Revolution in Urological Surgery Innovation

Annual Review | Academician Xu Zhang: Chinese Doctors Leading a New Revolution in Urological Surgery Innovation

2024.09.11
Time rewards those who strive, and success comes to those who persevere. As 2023 draws to a close, the year has left behind many noteworthy achievements in China’s field of urology, especially in the areas of prostate cancer surgery and drug treatments. On this occasion, Urology Frontier interviewed Xu Zhang, Academician of the Chinese PLA General Hospital and a pioneer in laparoscopic techniques in China’s urological surgery. In this interview, he shared significant developments in surgical and medical treatments for prostate cancer over the past year.
Dr. Wenbin Qian: Analyzing the Pros and Cons of CAR-NK Therapy and Future Research Directions

Dr. Wenbin Qian: Analyzing the Pros and Cons of CAR-NK Therapy and Future Research Directions

2024.09.11
In the realm of cellular therapy, CAR-NK technology is spearheading a new wave of treatment possibilities. Given the current state of cellular therapy in China, advancing technologies like CAR-NK has become crucial. At the 12th Lu Daopei Hematology Forum, Hematology Frontier had the privilege of inviting Dr. Wenbin Qian from The Second Affiliated Hospital Zhejiang University School of Medicine to provide an in-depth analysis of the benefits and challenges of CAR-NK therapy, explore future research directions, and discuss new chapters in cellular therapy.
Dr. Guohong Han’s Team: Measuring Portal Pressure Gradient 24 Hours Post-TIPS Provides More Accurate Risk Prediction for Complications

Dr. Guohong Han’s Team: Measuring Portal Pressure Gradient 24 Hours Post-TIPS Provides More Accurate Risk Prediction for Complications

2024.09.11
Portal hypertension is a severe complication of chronic liver disease, directly associated with clinical outcomes such as ascites and variceal bleeding. Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment that significantly reduces portal pressure. Portal pressure gradient (PPG) is commonly used to assess portal pressure in patients undergoing TIPS. Recently, a study conducted by Dr. Guohong Han's team from Xi'an International Medical Center Hospital that published in the Journal of Hepatology, explored the optimal timing of measurement and hemodynamic target of PPG in cirrhotic patients with variceal bleeding undergoing covered stent TIPS. Dr. Yong Lv from Xijing Hospital is the first author of this article, and Dr. Guohong Han is the corresponding author.